Glenmark Pharmaceutical’s Antiviral Drug Hits the Mark in Small, Phase III COVID-19 Study | BioSpace

An antiviral drug developed by Glenmark Pharmaceuticals boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.

Read the full article here

Related Articles